Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hafrun Fridriksdottir


  • Executive Vp, Global R&d at Teva Pharmaceutical Industries Ltd (TEVA), 2019-12-03
  • Svp, Global R&d at Actavis Plc (ACT), 2014-05-13
  • Sr Vp, Global Generics R&d at Actavis Inc. (ACT), 2013-10-03
Insider Trading: Sales See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
TEVA $10.49 4,310 Officer 20,573 2019-12-02 Filing
TEVA $16.63 93 Officer 16,750 2019-03-18 Filing
TEVA $16.63 263 Officer 16,843 2019-03-18 Filing
TEVA $16.88 409 Officer 16,094 2019-03-04 Filing
TEVA $17.67 1,841 Officer 15,338 2019-02-14 Filing